22:30 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

GAP3KO vaccine: Ph I data

An open-label, U.S. Phase I trial in 10 healthy volunteers showed that GAP3KO administered via the bite of 150-200 GAP3KO-infected mosquitoes under controlled conditions prevented malaria infection in all subjects. Specifically, all 10 subjects developed...
00:09 , Jan 5, 2017 |  BC Extra  |  Clinical News

Malaria vaccine shows promise in Phase Ia trial

In a study published Wednesday in Science Translational Medicine , researchers at the Center for Infectious Disease Research and Fred Hutchinson Cancer Research Center said a vaccine using genetically attenuated parasites prevented malaria infection in...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Plasmodium sporozoite asparagine-rich protein (SLARP); P. falciparum circumsporozoite protein B9 (B9; CSP)

Infectious disease INDICATION: Malaria In vitro and mouse studies suggest a genetically attenuated parasite could be used to vaccinate against malaria. Plasmodium berghei with engineered deletions of the B9 and SLARP genes - which are...